

LIDDS announces completion of stage 2 in R&D project with J&J

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company has completed the second phase of the on-going R&D collaboration project with Johnson & Johnson Enterprise Innovation Inc (J&J) and has delivered its final report.

The Joint Research Committee met last Friday where the LIDDS team delivered their final report as part of the on-going collaboration between LIDDS and J&J. The collaboration between LIDDS and J&J was formed in 2021 with the aim to develop an oncology product based on the NanoZolid® technology for an undisclosed indication. All results have now been communicated to J&J. The latter party will now consider these results and make a formal decision on whether to continue the program further.

“We have enjoyed the collaboration with J&J” says Matthew Lindon, Chief Scientific Officer at LIDDS. “The program was extended vs. the original plan. Now we have reached as far as we can within the scope of the current agreement. It is now up to J&J to decide on a possible continuation. We anticipate that J&J will make a formal decision on this in the relative near-term future”, he continues.

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com

Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS's Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS announces completion of stage 2 in R&D project with J&J